Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 122,000 shares, an increase of 60.7% from the February 28th total of 75,900 shares. Currently, 0.2% of the company's shares are short sold. Based on an average daily volume of 89,000 shares, the days-to-cover ratio is currently 1.4 days.
Alpha Tau Medical Stock Performance
Shares of NASDAQ DRTS traded down $0.05 during trading on Monday, hitting $2.51. 39,500 shares of the company traded hands, compared to its average volume of 48,679. Alpha Tau Medical has a fifty-two week low of $1.75 and a fifty-two week high of $4.39. The business's fifty day moving average is $3.08 and its 200 day moving average is $2.81. The firm has a market capitalization of $176.66 million, a price-to-earnings ratio of -5.84 and a beta of 0.87.
Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last issued its quarterly earnings data on Wednesday, March 12th. The company reported ($0.13) EPS for the quarter, hitting analysts' consensus estimates of ($0.13). On average, analysts predict that Alpha Tau Medical will post -0.45 EPS for the current year.
Hedge Funds Weigh In On Alpha Tau Medical
Several large investors have recently bought and sold shares of the stock. Levin Capital Strategies L.P. grew its stake in shares of Alpha Tau Medical by 2.3% in the 4th quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company's stock worth $975,000 after acquiring an additional 7,189 shares in the last quarter. Northern Trust Corp grew its position in Alpha Tau Medical by 112.6% in the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company's stock worth $151,000 after purchasing an additional 25,770 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in Alpha Tau Medical by 188.7% in the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company's stock worth $127,000 after purchasing an additional 26,800 shares in the last quarter. 2.65% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a "buy" rating and set a $9.00 price objective on shares of Alpha Tau Medical in a research report on Monday, March 17th.
Check Out Our Latest Stock Report on DRTS
Alpha Tau Medical Company Profile
(
Get Free Report)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
See Also
Before you consider Alpha Tau Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.
While Alpha Tau Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
